Synthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligands.

The CB2 receptor is a therapeutic target of increasing importance for several diseases, including pain, inflammation, neurodegeneration, cancer and osteoporosis. While several compounds showing CB2-selective agonist or inverse agonist properties have been developed, only few CB2 receptor selective neutral antagonists are actually known. Such type of compounds could be useful to study more in depth the role of the CB2 receptor, because they lack the ability to counteract its "constitutive" activity. Here we describe the synthesis and biological activity of a series of biphenylic carboxamides as a new class of CB2 receptor selective ligands. In binding assays, one of these compounds showed good CB2 receptor affinity and selectivity (Ki = 11.48 nM; Selectivity Index = 130). Furthermore, in functional assays, the same compound showed a very interesting pharmacological profile as CB2 receptor selective neutral antagonist. These results pave the way to further developments, including structural optimization, with the aim to obtain more potent CB2 receptor ligands with this peculiar feature.

[1]  G. Muccioli.  Blocking the Cannabinoid Receptors: Drug Candidates and Therapeutic Promises , 2007, Chemistry & biodiversity.

[2]  J. Laitinen,et al.  An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors , 2003, British journal of pharmacology.

[3]  E. Novellino,et al.  Beyond radio-displacement techniques for Identification of CB1 Ligands: The First Application of a Fluorescence-quenching Assay , 2014, Scientific Reports.

[4]  A. Malfitano,et al.  1,2-Dihydro-2-oxopyridine-3-carboxamides: the C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor. , 2014, European journal of medicinal chemistry.

[5]  A. Zimmer,et al.  Endocannabinoids and the Regulation of Bone Metabolism , 2008, Journal of neuroendocrinology.

[6]  P. Anand,et al.  Targeting CB2 receptors and the endocannabinoid system for the treatment of pain , 2009, Brain Research Reviews.

[7]  J. Romero,et al.  Cannabinoid CB2 receptors in human brain inflammation , 2008, British journal of pharmacology.

[8]  D. Centonze,et al.  The endocannabinoid system in targeting inflammatory neurodegenerative diseases. , 2007, Trends in pharmacological sciences.

[9]  Evangelia Kotsikorou,et al.  The importance of hydrogen bonding and aromatic stacking to the affinity and efficacy of cannabinoid receptor CB2 antagonist, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide (SR144528). , 2013, Journal of medicinal chemistry.

[10]  Xuqing Zhang,et al.  Novel fragmentation reaction of 2-alkyl- and 2,4-dialkyl-3-iodo-1-oxocyclohexan-2,4-carbolactones. , 2004, The Journal of organic chemistry.

[11]  R. Pertwee,et al.  Cannabinoid receptors and their ligands. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[12]  T. Vanderah,et al.  CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? , 2003, Current opinion in pharmacology.

[13]  H. Iwamura,et al.  In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. , 2001, The Journal of pharmacology and experimental therapeutics.

[14]  Hong Zhang,et al.  Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis , 2009, Inflammatory bowel diseases.

[15]  Qin Tong,et al.  Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors. , 2012, Journal of medicinal chemistry.

[16]  J. Balzarini,et al.  Enzymatically activated cycloSal-d4T-monophosphates: The third generation of cycloSal-pronucleotides. , 2007, Journal of medicinal chemistry.

[17]  P Pacher,et al.  Is lipid signaling through cannabinoid 2 receptors part of a protective system? , 2011, Progress in lipid research.

[18]  R. Abagyan,et al.  Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. , 2010, Journal of the American Chemical Society.

[19]  E. De Clercq,et al.  Synthesis, anti-HIV activity, and metabolic stability of new alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors. , 2005, Journal of medicinal chemistry.

[20]  D. Hurst,et al.  Endogenous lipid activated G protein-coupled receptors: emerging structural features from crystallography and molecular dynamics simulations. , 2013, Chemistry and physics of lipids.

[21]  B. Frenkel,et al.  Peripheral cannabinoid receptor, CB2, regulates bone mass. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  K. Varani,et al.  Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models , 2013, PAIN®.

[23]  R. Pertwee.  Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities , 2012, Philosophical Transactions of the Royal Society B: Biological Sciences.

[24]  T. Bisogno,et al.  Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. , 2010, CNS & neurological disorders drug targets.

[25]  A. Hohmann,et al.  Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain , 2008, British journal of pharmacology.

[26]  Cristina Tintori,et al.  Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB(2) cannabinoid receptor inverse agonists. , 2013, Journal of medicinal chemistry.

[27]  S. Skaper,et al.  Endocannabinoids in nervous system health and disease: the big picture in a nutshell , 2012, Philosophical Transactions of the Royal Society B: Biological Sciences.

[28]  C. Laezza,et al.  The endocannabinoid signaling system in cancer. , 2013, Trends in pharmacological sciences.

[29]  P. Pacher,et al.  The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.

[30]  A. Poso,et al.  Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands , 2008, British journal of pharmacology.

[31]  Hugh Rosen,et al.  Crystal Structure of a Lipid G Protein–Coupled Receptor , 2012, Science.

[32]  Remo Guidieri.  Res , 1995, RES: Anthropology and Aesthetics.

[33]  K. Mackie,et al.  Identification functional characterization of brainstem cannabinoid CB2 receptors. , 2022 .

[34]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[35]  Antti Poso,et al.  Identification of WIN55212‐3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor , 2005, British journal of pharmacology.

[36]  M. Cascio,et al.  In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists. , 2010, Pharmacological research.

[37]  J. Hartwig,et al.  Air Stable, Sterically Hindered Ferrocenyl Dialkylphosphines for Palladium-Catalyzed C−C, C−N, and C−O Bond-Forming Cross-Couplings , 2002 .

[38]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[39]  R. Pertwee,et al.  Emerging strategies for exploiting cannabinoid receptor agonists as medicines , 2009, British journal of pharmacology.

[40]  S. Ralston,et al.  Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. , 2008, Endocrinology.

[41]  B. Frenkel,et al.  CB2 Cannabinoid Receptor Targets Mitogenic Gi Protein–Cyclin D1 Axis in Osteoblasts , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[42]  K. Rice,et al.  Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. , 1993, The Journal of pharmacology and experimental therapeutics.

[43]  C. Pannecouque,et al.  Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability. , 2007, Journal of medicinal chemistry.

[44]  K. Mackie,et al.  CB2 cannabinoid receptor agonists attenuate TNF‐α‐induced human vascular smooth muscle cell proliferation and migration , 2008, British journal of pharmacology.

[45]  D. Wyllie,et al.  Taking The Time To Study Competitive Antagonism , 2007, British journal of pharmacology.

[46]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[47]  P. Chandran,et al.  In vitro and in vivo characterization of A‐796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models , 2008, British journal of pharmacology.

[48]  Tod D Romo,et al.  A Lipid Pathway for Ligand Binding Is Necessary for a Cannabinoid G Protein-coupled Receptor* , 2010, The Journal of Biological Chemistry.

[49]  O. Daugulis,et al.  Carbon-hydrogen bond functionalization approach for the synthesis of fluorenones and ortho-arylated benzonitriles. , 2008, The Journal of organic chemistry.